Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Contacts
Similar Companies1000
Kanaph Therapeutics
Kanaph Therapeutics is a biotech company that develops next-generation therapeutics for oncology and autoimmune diseases.
Sector
Subsector
Location
total rounds
total raised
Galapagos
Galapagos is a clinical-stage biotechnology company that discovers and develops small molecule medicines with novel modes of action.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
Genosco
Genosco is a clinical-stage biotech company that develops small-molecule drugs for patients with unmet medical needs.
Sector
Subsector
Location
Belharra Therapeutics
Belharra Therapeutics is a drug discovery company specializing in transformative medicines.
Sector
Subsector
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Gilead Sciences
announced date
Financials
Funding Rounds3
Number of Funding Rounds
Money Raised
Their latest funding was raised on 04.08.2021. Their latest investor TTM Capital. Their latest round Series B
OrbiMed
OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Foresite Capital
Foresite Capital is a healthcare and life sciences investment firm with $2 billion under management.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
TTM Capital
TTM Capital, LLC offers investment advisory and management services to investors looking to invest in financial asset pools.
Sector
Subsector
Keywords
count Of Investments
Co-Investors
Investors3
Number of lead investors
Number of investors
TTM Capital
TTM Capital, LLC offers investment advisory and management services to investors looking to invest in financial asset pools.
Sector
Subsector
Keywords
count Of Investments
OrbiMed
OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Carl L. Gordon
Carl Gordon is a founding General Partner of OrbiMed and Co-Head of Private Equity. Carl Gordon is active in both private equity and small-capitalization public equity investments.He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997.He was a Fellow at The Rockefeller University from 1993 to 1995. Carl Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a Bachelors degree from Harvard College.
current job
Foresite Capital
Foresite Capital is a healthcare and life sciences investment firm with $2 billion under management.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Jim Tananbaum
Dr. Tananbaum is the founding CEO of Foresite Capital Management. He has led investments in 21 successful healthcare companies, including Amira Pharmaceuticals (acquired by Bristol-Myers Squibb), Amerigroup and Jazz Pharmaceuticals. Previously, Dr. Tananbaum founded and held management positions at GelTex Pharmaceuticals (acquired by Genzyme for $1.6B) and Theravance. He holds an M.D. from Harvard Medical School and an M.B.A from Harvard Business School, and a B.S. and B.S.E.E. from Yale University. Dr. Tananbaum has served on the advisory boards and/or visiting committees to the Harvard-MIT HST program and Yale School of Engineering.
current job
organization founded
Michael Rome
Michael Rome is a Managing Director at Foresite Capital.
People
Founders3
Qing Dong
Qing Dong is a President & CSO, of Xinthera Inc.
current job
organization founded
Qing Dong
Stephen Kaldor
Steve is a Venture Partner with Versant Ventures and is also the CEO of Quanticel Pharmaceuticals, a privately held Versant portfolio company focused on cancer drug discovery. Steve was CEO of Ambrx from 2007-2010 and helped this biologics company mature its drug portfolio and platform through deals with Pfizer, Merck, Lilly, and Merck-Serono. Steve served as President & CSO of Syrrx from 2002-2005, and led the company through its $270M acquisition by Takeda in 2005 and for several years post acquisition. Prior to joining Syrrx, Steve gained 12 years of R&D experience at Eli Lilly as both a researcher and Director. A chemist by training, Steve is a co-inventor of ten therapeutic compounds that have entered the clinic including Viracept, a marketed AIDS medication, and Nesina, a marketed diabetes medication. Steve also serves as an independent board member for various companies including Furiex (2010 – current), Amira (2008 through 2011 acquisition by BMS) and Anaphore (2008 – 2011). He received a PhD from Harvard University and a BA from Columbia University.
current job
Stephen Kaldor
Gene Hung
Gene Hung is a Co-founder and Senior Vice President at Xinthera Inc.
current job
organization founded
Gene Hung
